Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

Publikation: Bidrag til tidsskriftReviewpeer review

  1. Pharmacotherapeutic considerations in women with multiple sclerosis

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Treatment of adult short bowel syndrome patients with teduglutide

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Irinotecan and bevacizumab in recurrent glioblastoma multiforme

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Therapeutic management of type 1 diabetes before and during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  5. Treating tension-type headache -- an expert opinion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Six-day subcutaneous GIP infusion increases glycaemic time in range in patients with type 1 diabetes

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  3. Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  • Sebastian M Heimbürger
  • Andreas Brønden
  • Nicklas J Johansen
  • Thomas F Dejgaard
  • Tina Vilsbøll
  • Filip K Knop
Vis graf over relationer

INTRODUCTION: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Pharmacotherapy
Vol/bind20
Udgave nummer5
Sider (fra-til)501-510
Antal sider10
ISSN1465-6566
DOI
StatusUdgivet - 2019

ID: 56500407